Bryan, Garnier & Co Reiterates Buy Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reaffirmed by analysts at Bryan, Garnier & Co in a research note issued on Monday.
Other analysts have also issued research reports about the stock. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday, June 20th. HSBC reiterated a “buy” rating and set a GBX 1,970 ($24.38) price objective on shares of GlaxoSmithKline plc in a research note on Monday, September 12th. Deutsche Bank AG reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research note on Monday, June 27th. Berenberg Bank set a GBX 1,885 ($23.33) price objective on shares of GlaxoSmithKline plc and gave the company a “neutral” rating in a research note on Tuesday, August 9th. Finally, Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline plc in a research note on Tuesday, June 21st. Three analysts have rated the stock with a sell rating, fifteen have issued a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of GBX 1,687.13 ($20.88).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1685.24 on Monday. The stock has a 50 day moving average of GBX 1,650.69 and a 200-day moving average of GBX 1,561.99. The stock’s market capitalization is GBX 81.92 billion. GlaxoSmithKline plc has a 1-year low of GBX 1,277.25 and a 1-year high of GBX 1,745.56.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/bryan-garnier-co-reiterates-buy-rating-for-glaxosmithkline-plc-gsk.html
The firm also recently declared a dividend, which was paid on Thursday, October 13th. Shareholders of record on Thursday, August 11th were given a GBX 19 ($0.24) dividend. This represents a yield of 1.12%. The ex-dividend date of this dividend was Thursday, August 11th.
In other GlaxoSmithKline plc news, insider Witty,Sir Andrew P sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.95), for a total value of £169,300 ($209,529.70). Also, insider Slaoui,Moncef purchased 28 shares of the company’s stock in a transaction on Friday, August 12th. The stock was acquired at an average price of GBX 2,208 ($27.33) per share, for a total transaction of £618.24 ($765.15).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.